CXCL8 and COVID-19: Immediately after the start of the pandemic, we had suggested reparixin (also called repertaxin), a non-competitive allosteric inhibitor of the CXCL8 (IL-8) receptors C-X-C chemokine receptor type 1 (CXCR1) and C-X-C chemokine receptor type 2 (CXCR2), as a potentially effective molecule after the successful treatment of four patients with extremely severe COVID-19 (3).